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The Optimal Intensity of Vitamin K
Antagonists in Patients With
Mechanical Heart Valves: A Meta-analysis
I enjoyed the article by Vink et al. (1), which again revisits
an old and most important clinical chestnut, but I have
serious misgivings about their conclusions. Some years ago,
we did a detailed and comprehensive analysis of 1,134
patients who had received St. Jude prosthetic valve(s) over a
13-year period (2). The follow up was 100% complete—
4,936 patient years—and the study had a 60% post-mortem
examination rate for early deaths.
The recommendation we made as the result of our
analysis, namely that the INR should be kept between 2.5
and 3.0, is at complete variance with that of the authors. I
believe that the problem arises from the fact that the target
international normalized ratio (INR) range on which the
authors focused may have no bearing whatsoever on the
INR at the actual time of the anticoagulant-related compli-
cation. In contrast, we based our recommendations on the
INR measured at the actual time of the anticoagulant-related
complication, which we had in 88% and 58% of the major
thromboembolic and hemorrhagic complications, respec-
tively. Furthermore, in a more recent study (3), we found
that at any given time 21.8% to 32.5% of patients were
outside the target INR set for them; indeed, other authors
have found an even greater number of patients (up to 52%)
outside the target INR range (4).
It is essential therefore to base any recommendation
regarding anticoagulation on an analysis of INR readings at
the actual time of the anticoagulant-related complications
rather than the target INR range, which is the ideal rather
than the reality.
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Anticoagulation Management
of Patients With Prosthetic Valves
As authors of previous European guidelines on anticoagu-
lation of patients after valve surgery and as members of a
committee currently revising those guidelines, we are con-
cerned to read the paper of Vink et al. (1) Their recom-
mendation that all patients should be managed with an
international normalized ratio (INR) of 3.0 to 4.5 reverses
current trends to individualize antithrombotic management
for each patient based on an assessment of their particular
thromboembolic risk (2–4). Although having a “one size fits
all” approach to anticoagulation management may have
advantages for anticoagulation clinics, this approach will not
benefit individual patients who may be exposed to the risks
of unnecessarily high anticoagulation.
Their meta-analysis raises several concerns. First, meta-
analysis is a technique for amalgamating data from random-
ized controlled trials (RCT) that have used the same
methodology, not observational studies with different meth-
odology. Second, reported thromboembolic rates are heavily
influenced by definitions, data collection methods (prospec-
tive vs. retrospective), size and length of study, patient risk
factors, concomitant surgery, and type of prosthesis (5,6).
Other than the prosthetic type, these factors are not
mentioned. Valve thrombosis rates are influenced by the
number of patients who experienced anticoagulation inter-
ruption, to which most cases are related (7). Third, we
question the use of target INRs rather than achieved INRs.
Many events occur when the INR is outside the target
range.
Fourth, retrospective conversion of prothrombin time
ratios to INR has the potential to introduce huge errors. In
American studies, it is highly unlikely that a single throm-
boplastin reagent would have been used for all patients in
the study (8).
Finally, there is a lack of acknowledgment of the five
published RCTs comparing different anticoagulation inten-
sity (9–13). Although most of these RCTs have limited
applicability because of their methodologies, all reached the
conclusion that a higher intensity of anticoagulation did not
reduce the incidence of thromboembolism. Four RCTs
showed a higher incidence of bleeding with higher intensity
anticoagulation. The only RCT not to show this effect used
overlapping INR ranges and did not record events in the
first three months (13).
Although Vink et al. (1) acknowledge that high-intensity
anticoagulation results in a higher incidence of bleeding,
they appear to minimize this danger. Use of a higher range
of INR, 3.0 to 4.5, for all patients imposes an imperative for
extremely tight INR control. High variability of INR, with
30% of INRs outside the range 2.0 to 4.0, is the strongest
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